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The objective of the Hereditary Angioedema Burden 
of Illness Study in Europe was to assess the real-world 
experience of hereditary angioedema (HAE) from the 
patient perspective. Based on open-ended qualitative 
interviews with 30 patients from Spain, Germany and 
Denmark, 5 key themes emerged characterizing the im-
pact of HAE on health-related quality of life (HRQoL): 
(i) unnecessary treatments and procedures, (ii) symptom 
triggers, (iii) attack impacts, (iv) caregiver impacts, and 
(v) long-term impacts. Patients for example experience 
unnecessary medical procedures due to diagnostic de-
lays; anxiety and fear about attacks, and passing HAE 
to children; reduced work/school productivity; and limi-
ted career/educational achievement. Patient caregivers 
also experience worry and work/activity interruption 
during the attacks. In conclusion, a conceptual model 
was developed illustrating the hypothesized relation-
ships among the wide-ranging short- and long-term 
HRQoL impacts of HAE. These findings can be used to 
highlight important issues in clinical management, raise 
awareness of the patients’ experience among policyma-
kers and help guide measurement of HRQoL outcomes 
in future studies in HAE. Key words: burden of illness; 
conceptual model; health-related quality of life; hereditary 
angioedema; HAE; C1-inhibitor deficiency.
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Hereditary angioedema (HAE), a rare and potentially life-
threatening disorder caused by C1-inhibitor deficiency, 
is characterized by spontaneous, recurrent attacks of 
swelling in various regions of the body (1, 2). During an 
HAE attack, patients may experience disfiguration, severe 
pain and inability to perform daily activities. Symptoms 
typically last for 1–4 days and frequency may range from 
almost none to 1 every 3 days (3, 4). Many patients have 
ancestors who died of asphyxiation due to laryngeal swel-
ling, causing the patients to live in constant fear (3–6). 
HAE treatment aims to reduce the physical seve-
rity and frequency of attacks, and several consensus 
documents for the management of HAE have been 
developed (7–11). However, little qualitative research 
has been conducted focusing on health outcomes from 
the patient’s perspective, especially among adolescents 
and young adults. Conceptual models can be a useful 
way to illustrate the full range of ways in which a 
particular disease affects health-related quality of life 
(HRQoL) (12), Conceptual models developed in the 
patient-reported outcomes (PRO) field are detailed 
models that can be used to identify important concepts 
that could be measured as end-points in a clinical study 
and generally include the domains of physical, social 
and psychological functioning (13).
The Hereditary Angioedema Burden of Illness Study 
in Europe (HAE-BOIS-Europe) was a cross-sectional 
study undertaken to capture the HRQoL and economic 
burden of HAE comprehensively from the patient per-
spective. The study contained both quantitative and 
qualitative methodologies (14). This article focuses 
on the findings from the qualitative component, which 
involved one-on-one, open-ended interviews with HAE 
patients. The data from these interviews were used to 
guide the development of a conceptual model illustra-
ting the impact of HAE from the patient perspective.
MATERIALS AND METHODS
The HAE-BOIS-Europe was conducted in Spain, Germany 
and Denmark, between May and December 2011. The 2 study 
components were: (i) a one-time web- or paper-based survey 
on the humanistic and economic burden of HAE (14–16); and 
(ii) open-ended patient interviews. Interviews were conducted 
with 10 participants with HAE per country. A sample of 30 
participants was selected based on an industry task force report 
generally recommending a sample size of 20–30 participants for 
qualitative research (17). Interview participants were selected 
from clinical practice centres of excellence, taking a purposive 
sampling approach with an aim to recruit a mix of participants 
based on gender, age, disease severity, attack frequency, loca-
tion of swelling and treatment type. To be eligible, participants 
had to be at least 12 years of age, with HAE Type 1 or 2. The 
full methodology is described in Bygum et al. in 2012 (14). 
The interviews were conducted over the telephone in the local 
language by an interviewer trained in qualitative research (by 
the research group Oxford Outcomes). Interviewers followed 
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a semi-structured interview guide consisting of open-ended 
questions with additional probing questions as needed for 
further clarification of responses. The interview guide had 4 
parts, with questions on demographics, clinical characteristics, 
the impact of HAE on daily life during attacks and in between 
attacks, and treatment history. On average, the interviews 
lasted approximately 30 min. Interviews were audio-recorded, 
transcribed verbatim, and translated into English. 
Analysis involved a repeated review of the transcripts and was 
modelled after the framework approach, an applied qualitative 
analysis methodology, in which coded text, where 
the text is labelled into categories, is organized in 
a table by each individual respondent so that the 
context of the individual’s views is not lost (18, 19). 
Analysis involved deduction to answer the a priori 
research questions; specifically, what is the impact of 
attacks on daily activities, and what is the impact of 
HAE when not having an acute attack. An inductive 
approach, in which categories or themes are iden-
tified based on the data and used to build theory, 
was used to identify all additional key themes. A 
conceptual model was developed, summarizing the 
themes identified and the hypothesized relationships 
among them. The conceptual model was reviewed 
and further refined and finalized by all of the authors 
in a consensus meeting.
RESULTS 
Demographic and clinical characteristics. 
Among the 30 participants, 18 (60%) were 
females, the mean age was 41 years (range 
15–71 years; 5 (17%) aged 25 years or 
younger) and 20 (67%) were employed full- 
or part-time or were in education. These 
results were similar to those obtained in the 
quantitative study, with 60% of patients be-
ing female, a mean age of 43 years and 73% 
employed full- or part-time or studying (15, 
16). Participants first experienced HAE symp-
toms at a mean ± SD of 31.1 ± 16.0 years ago 
and received their HAE diagnosis 14.9 ± 9.4 
years ago. Twenty participants (71%) had had 
an HAE attack within the past 30 days. The 
most common body parts affected by the last 
attack were the abdomen and extremities, 
each reported by 12 people (41%). Twelve 
participants (41%) reported that their attack 
lasted 1–2 days and 8 (28%) reported that it 
lasted less than 12 h, also comparable to the 
quantitative study (15). Six (20%) reported 
their overall health as “fair” as opposed to 
“good” or “better” (Table I). 
Burden of illness
Fig. 1 shows the key themes that were iden-
tified, which were consistent across the 3 
countries, and the hypothesized relationships 
among them. The qualitative analysis of the 
data yielded 5 main areas, which characterize the bur-
den of HAE: unnecessary treatments and procedures, 
symptom triggers, attack impacts, caregiver impacts 
and long-term impacts.
Unnecessary treatments and procedures. Many participants 
underwent unnecessary treatments and procedures while await-
ing an accurate diagnosis. This included treatment for arthritis, 
appendicitis, food allergies and stomach ulcers. Several partici-
pants had unnecessary surgeries for these conditions, and now 









Female, n (%) 18 (60) 6 (60) 6 (60) 6 (60)
Age, years, mean ± SD
  Age range, n (%)
    15–25 years
    26–45 years
    46–65 years
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  Less than high-school
  High-school diploma
  Technical/vocational 
  University coursework/degree





















Employment status, n (%)
  Employed full-time





























Years since first experiencing 
HAE symptoms, mean ± SD
31.1 ± 16.0 28.0 ± 14.3b 26.3 ± 14.8 38.7 ± 17.2
Years since receiving HAE 
diagnosis, mean ± SD
14.9 ± 9.4 16.5 ± 14.3 17.4 ± 9.7 13.8 ± 11.5
Time since last attack, n (%)
  0–30 days
  1–3 months
  3–6 months
















































Duration of attack, n (%)
  < 12 h
  12–24 h
  1–2 days
  > 2–3 days


























Overall health, n (%)
  Excellent
























aMaternity leave, disability, and self-employed (full-time/part-time unspecified). bResponse 
missing from one participant. SD: standard deviation; HAE: hereditary angioedema.
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have permanent scars. Participants stressed a need for greater 
awareness of HAE among clinicians and the general public. 
Table SI1 presents selected quotes referring to unnecessary 
testing and treatments.
Symptom triggers. During acute attacks, participants expe-
rienced pain and swelling, which may have developed sponta-
neously, but was often preceded by accidents, illness, exercise, 
stress, or hormone changes. Triggers included knitting, garde-
ning, falling while skiing, wearing high heels, catching a cold, 
hormone changes and stressful days or phases of life. Table SI1 
presents selected quotes referring to symptom triggers.
Attack impacts. Table SII1 presents selected quotes referring to 
attack impacts. Attack symptoms included pain, swelling, and 
asphyxiation. Attacks have a substantial impact on daily acti-
vities, including the ability to perform household tasks, drive, 
participate in family activities, travel, or follow through on 
plans; some participants had been bedridden during attacks. The 
duration of activity disruption varied, but in many cases lasted 
1–2 days. Participants largely considered abdominal attacks to 
involve the most severe pain. They could last for several days, 
and be accompanied by vomiting, and 
may have forced the participant to be 
confined to bed. Swollen feet may also 
prevent the participant from being able 
to get out of bed, but participants gene-
rally considered extremity attacks to be 
less painful, though not necessarily less 
severe. Extremity attacks prevented 
participants from being able to do daily 
tasks involving the hands and feet, such 
as using a computer or driving.
The inability to perform normal ac-
tivities during attacks caused interrup-
tion to participants’ work or schooling, 
including absenteeism and decreased 
productivity. Participants mentioned 
that there are job tasks that they are 
unable to perform when they are having 
an attack, and attacks often required 
participants to take time off from their 
job. One participant mentioned that he 
had to be prepared to work from home 
or the hospital at any time because there 
were times when he could not be absent 
from his work for any reason.
Participants felt a great deal of 
emotional distress during attacks. Par-
ticipants were anxious and fearful of 
the attack getting worse or potentially 
not being able to breathe. They feared 
that they would not be able to get to 
the hospital in time in the event of a 
laryngeal attack. Patients also expe-
rienced anxiety due to activity limita-
tions during attacks, such as not being 
able to participate in family activities. 
Attack modifiers. Symptom modifiers 
included the availability of treatment 
for acute attacks, pre-procedural pro-
phylaxis, and long-term prophylaxis, 
and patient education and the ability to 
self-administer acute medication. Ha-
ving access to treatment eased patients’ 
anxiety and improved their sense of 
control and independence. Attacks were shorter when treated 
quickly, reducing the duration of their impact on HRQoL, and 
in some cases, caregivers were taught to administer the injec-
tion to the patient, which further reduced the patient’s anxiety. 
Pre-procedural prophylaxis helped prevent attacks resulting 
from dental or medical procedures, and long-term prophylaxis 
typically reduced the frequency of attacks.
Attack­related resource utilization. Some participants reported 
that they self-injected their acute medication during attacks, 
while others routinely go to the hospital emergency department 
for their injection. The need to travel to the hospital or clinic 
for an injection was reported to be inconvenient. One partici-
pant mentioned that she often must wait until the next morning 
when her child is at daycare to go to the hospital for treatment 
if she is unable to find a babysitter, forcing her to endure long 
periods of pain. Attack-related costs were primarily related to 
medications and treatment visits, including co-payments and 
supplies, such as syringes and alcohol swabs, or travel expenses 
to the health centre, such as taxis, parking and fuel. 
Caregiver impacts. Participants perceived that attacks have 
a substantial impact on their caregivers, who were primarily 
family and friends. This included an emotional burden of 
needing to be prepared to take their loved one for treatment 
Fig. 1. Conceptual model. ADL: activities of daily living; HAE: hereditary angioedema.
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2014
Acta Derm Venereol 95
709Burden of illness in hereditary angioedema
if needed or to administer the injection. Concerns were also 
expressed about the need to take on additional responsibilities 
in the home while the patient is ill. Participants indicated that 
their caregivers had to miss work at times to accompany them 
to the hospital during severe attacks.
Long­term impacts. The impact of recurrent, unpredictable 
acute attacks had long-term implications for the participants, 
including psychosocial issues, career and educational setbacks, 
as well as impacts on long-term resource utilization. Table SIII1 
presents selected quotes referring to long-term impacts of HAE. 
Psychosocial impacts. Participants experience long-term psy-
chosocial impacts, including anxiety about having children, 
worry, and social/relationship impairment. Some chose not to 
have children or to have fewer children than desired, which 
caused emotional distress and may have contributed to marital 
problems. Many felt forced to avoid travelling, certain hob-
bies, or social opportunities, and consequently felt that their 
relationships suffered.
Career and educational impacts. Due to their anxiety about 
future attacks and the unpredictable nature of HAE, some parti-
cipants felt that their career choices were limited or experienced 
setbacks in their career. Some felt that they could only work 
part-time, were unable to perform certain job tasks, or were 
unable to keep up with work due to frequent missed days. One 
participant reported that having HAE caused her to take much 
longer than expected to complete her education. Some perceived 
discrimination in the workplace or a lack of understanding or 
assistance from their co-workers. Participants feared that they 
would not be able to complete their work at times, and they 
could potentially lose their jobs. 
Long­term resource utilization. Resource utilization between 
attacks included missed time from work for routine care visits, 
prescription co-payments for prophylaxis for HAE. This could 
occasionally include their children as well. Other costs included 
travel expenses, such as fuel, tolls and parking. Patients who take 
long-term oral prophylaxis therapy may experience bothersome 
side-effects, which may lead to discontinuation. In some cases, 
long-term prophylaxis was ineffective. Others worried about 
potential long-term consequences that the medication might have. 
Adolescents/young adults. The 5 participants between the ages 
of 15 and 25 years identified some impacts found to be unique 
within this age group. In some cases, the adolescent/young 
adult had a parent with HAE, and therefore was diagnosed with 
HAE either before symptom onset or shortly thereafter. An early 
diagnosis prevented these patients undergoing any unnecessary 
treatment prior to diagnosis. Adolescents noted that having HAE 
impaired their participation in school activities and that they 
were unable to keep up with their peers: “Mostly, it limits my 
ability to do any physical sport...for example, during physical 
education class at school, I can’t do all the same things as my 
classmates….I have to do a lot less physically.” They expressed 
some anxiety about potentially not being able to achieve every-
thing they would like to in the future given their diagnosis: “You 
think about having children, a family, an education. And one 
thinks that it wouldn’t be possible to handle all this.”
DISCUSSION 
The findings from the qualitative research demonstrate 
the wide-ranging impact of HAE on a patient’s life. 
Part of the HAE humanistic and economic burden has 
been described previously (15, 20, 21). HAE not only 
causes substantial short-term disability associated with 
attacks, but, in between attacks, patients may live in 
persistent anxiety and disappointment, being preven-
ted from participating in selected activities. As such, 
patients experience substantial psychosocial burden 
living day-to-day with HAE. The long-term effects of 
the disease on the patient’s lifestyle, emotional health, 
career, educational attainment, family life and medical 
resource utilization have important and lasting effects, 
and may also affect caregivers’ quality of life.
The conceptual model (see Fig. 1) provides a means 
of presenting and organizing these different ideas into 
a schema. The model allows us to understand the dif-
ferent ways that people’s lives are affected in general 
by HAE (there may still of course be idiosyncratic 
impacts that go beyond the model). Based upon the 
qualitative work the conceptual model allows us to plan 
how patient-centred outcomes should be captured in 
clinical trials and other studies. The model could also 
be used to generate hypotheses and predictions, which 
could be subsequently tested. This indeed could help 
to refine the model. 
This approach to understanding the wider burden of 
disease in HAE can find some parallels in the literature, 
which underline the usefulness of this methodology. 
Buchbinder et al. (22), for example, undertook a very 
similar exercise to understand the impact of low-back 
pain. This research mapped out the main impact of 
back pain, but also identified domains not previously 
considered, including loss of independence and worry 
about the future. 
A strength of this study is that participants were 
chosen from 3 countries with different approaches to 
treatment, including varying availability of long-term 
prophylaxis medications. Despite several available 
treatments in 2011, the findings highlight an unmet 
need for more effective treatments of HAE attacks. 
This could help to alleviate patients’ anxiety, reducing 
activity limitations, improving ability to participate in 
hobbies, and improving chances for long-term success 
in their careers and personal lives. 
The interview participants were recruited non-
systematically, subjecting the conceptual model results 
to potential selection bias. Demographic and clinical 
characteristics were highly consistent with the HAE-
BOIS-Europe survey participants (15), suggesting that 
the interview participants were representative of the 
overall study population. Although we studied only 30 
patients, the sample provided a rich source of data for 
identifying and characterizing the key impacts of living 
with HAE. Only 5 participants were aged 25 years or 
younger, which limited our ability to draw conclusions 
about their unique experience in comparison with 
older participants. Moreover, some of the categories 
in the conceptual model are overlapping. It would be 
useful to further substantiate the findings in this study 
and potentially develop clearer distinctions among the 
categories in future larger-scale quantitative modelling 
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studies. We recommend additional research to further 
explore the impact of HAE on young people in many 
more countries. The burden and impact of HAE may 
be very different where people do not have access to 
acute treatments. 
In conclusion, it is not only the acute attack itself 
that affects the HAE patient’s quality of life, but people 
with HAE experience long-term lifestyle modifications 
to accommodate their disease. In addition, caregivers 
often share the burden of HAE. The conceptual model 
highlights important issues for consideration in the 
clinical management of HAE patients. This model helps 
to advocate for patients and to improve support and 
services. The conceptual model should raise awareness 
of the patient’s experience of HAE among policymakers 
and the healthcare community, and help to guide mea-
surement of HRQoL outcomes in future evaluations of 
treatment effectiveness in HAE. 
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